NEW YORK — Medidata, a developer of life science data management and analysis software, said on Friday that it has partnered with non-profit Project ALS to study amyotrophic lateral sclerosis (ALS) using the company's machine learning-based Rave Omics biomarker discovery platform.
According to Medidata, Rave Omics is designed to capture and analyze genomic, proteomic, transcriptomic and other omic data during clinical studies in order to identify biomarkers that can be used for patient stratification. Rave Omics is managed by Medidata subsidiary Acorn AI.